Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
US RNAi therapeutics company Alnylam Pharmaceuticals announced the US Food and Drug Administration (FDA) approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, Amvuttra (vutrisiran). 21 March 2025
Related News
Insights
Company Spotlight
A clinical-stage company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
The International Finance Facility for Immunization (IFFIm) has announced the settlement of its £300 million ($407 million), three-year 4.25% fixed-rate bond that was announced on June 3. 14 June 2025
Biotechnology
COVID success story BioNTech is to buy fellow German mRNA company CureVac. 12 June 2025
Biotechnology
USA-based biotech Vaxart has reported positive top-line results from a Phase I trial comparing its second-generation oral pill norovirus vaccine constructs to its first-generation constructs. 12 June 2025
Pharmaceutical
US biotech Novavax has reported that its experimental combination COVID-19 and influenza vaccine generated immune responses on par with approved shots in a descriptive Phase III trial involving older adults. The company said the results would help shape a future registrational study. 12 June 2025
Pharmaceutical
Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement. 11 June 2025
Pharmaceutical
USA-based Insmed Incorporated closed Tuesday’s trading up by more than a third. 11 June 2025
Biotechnology
South Korean biotech AriBio Co, specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi, announced an exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease. 11 June 2025
Pharmaceutical
Gilead Sciences has paused five clinical trials of its investigational HIV drugs GS-1720 and GS-4182 after the American medicines regulator raised safety concerns. The once-weekly oral regimen was being studied as an alternative to the company’s blockbuster daily pill, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide). 11 June 2025
Biotechnology
Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene therapy, SB-007, for Stargardt disease and expand its broader pipeline of genetic medicines. 11 June 2025
Pharmaceutical
Last month, the Future Health Report was presented at the World Health Assembly in Geneva, Switzerland. 10 June 2025
Latest In Brief for Alnylam Pharmaceuticals
Pharmaceutical
Shares of Swedish drugmaker Camurus shot up 23% to 638.50 kronor yesterday on news of that it has entered a collaboration and license agreement with Eli Lilly, granting the US pharma major exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology. 6 June 2025
Latest Relevant Ones To Watch News
COVID success story BioNTech is to buy fellow German mRNA company CureVac. 12 June 2025
16 May 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze